Real-World data reveals omalizumab prescribing patterns for chronic hives in china
NCT ID NCT07450170
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examined how the drug omalizumab is prescribed in real-world practice for adults with chronic urticaria (long-term hives) in China. Researchers analyzed electronic health records from over 3,400 patients to see what doses were commonly used. The goal was to understand treatment patterns, not to test a new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
Shanghai, 201203, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.